Zepzelca – Talk Bio

Actionable Insights Powered by AI

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

2 weeks ago talkbio0Tagged ASCO, atezolizumab, IMforte trial, Jazz, lurbinectedin, Malignant neoplasm of lung, Overall Survival, Progression-Free Survival, Small cell carcinoma of lung, Tecentriq, Zepzelca

Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025

Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer

8 months ago talkbio0Tagged atezolizumab, ES-SCLC, first-line, Jazz, lurbinectedin, Phase 3 IMforte trial, Small cell carcinoma of lung, Zepzelca

Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial